| human | Q5 |
| P6178 | Dimensions author ID | 01006220174.19 |
| P496 | ORCID iD | 0000-0002-9935-3169 |
| P69 | educated at | University of Manchester | Q230899 |
| MRC Human Genetics Unit | Q6717453 | ||
| P108 | employer | University of Southampton | Q76473 |
| University of Edinburgh | Q160302 | ||
| Central Manchester University Hospitals NHS Foundation Trust | Q5061394 | ||
| NHS Lothian | Q6954149 | ||
| University Hospital Southampton NHS Foundation Trust | Q20712409 | ||
| P734 | family name | Eccles | Q4530246 |
| Eccles | Q4530246 | ||
| Eccles | Q4530246 | ||
| P735 | given name | Diana | Q645412 |
| Diana | Q645412 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q50419884 | "It's Like We Don't Exist": Tailoring Education for Young Women Undergoing Surgery for Early-Stage Breast Cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q64004350 | A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer |
| Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
| Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
| Q37272982 | A genome wide linkage search for breast cancer susceptibility genes |
| Q34744122 | A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis |
| Q29417084 | A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. |
| Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
| Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
| Q42476404 | A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. |
| Q24803362 | A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer |
| Q55561844 | A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations. |
| Q36695547 | A randomised comparison of UK genetic risk counselling services for familial cancer: psychosocial outcomes. |
| Q34974010 | A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis |
| Q35435510 | A survey of the current clinical facilities for the management of familial cancer in Europe. European Union BIOMED II Demonstration Project: Familial Breast Cancer: audit of a new development in medical practice in European centres |
| Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
| Q34546389 | ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles |
| Q57903143 | Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22 |
| Q64004371 | Abstract |
| Q58053990 | Abstract B046: Therapeutic targeting of integrin αvβ6 in high-risk breast cancer |
| Q40310188 | Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage |
| Q43613838 | Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom |
| Q38406780 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study |
| Q52647897 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. |
| Q28603931 | An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients |
| Q35198352 | An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis |
| Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
| Q33716808 | An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation |
| Q45108358 | Analysis of KLLN as a high-penetrance breast cancer predisposition gene |
| Q34571320 | Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer |
| Q35359948 | Analysis of genetic and phenotypic heterogeneity in juvenile polyposis |
| Q36831854 | Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome |
| Q36649112 | Apoptosis, ageing and cancer susceptibility. |
| Q30276986 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q37684409 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
| Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
| Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
| Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
| Q39423088 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study |
| Q119213340 | Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q28186195 | Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH |
| Q24531993 | Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies |
| Q35350825 | BRCA1 Circos: a visualisation resource for functional analysis of missense variants |
| Q37261138 | BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk |
| Q37220433 | BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance |
| Q43073200 | BRCA1 mutation and neuronal migration defect: implications for chemoprevention. |
| Q35832295 | BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q33844055 | Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q43073201 | Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies |
| Q91662008 | Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study) |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q64004343 | Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation |
| Q90315966 | Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network |
| Q37364135 | Cancer genetics services in Europe |
| Q55560458 | Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy. |
| Q44946113 | Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. |
| Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q35782435 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer |
| Q55210447 | Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. |
| Q102151566 | Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations |
| Q35668946 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk |
| Q36490507 | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). |
| Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
| Q24655824 | Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q34949394 | Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q36255665 | Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer |
| Q37434133 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q37557334 | Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice |
| Q46084460 | Composite likelihood-based meta-analysis of breast cancer association studies. |
| Q34342248 | Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk |
| Q37533025 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer |
| Q30660858 | Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer |
| Q57266888 | Current Policies for Surveillance and Management in Women at Risk for Breast and Ovarian Cancer: A Survey among 16 European Family Cancer Clinics |
| Q50638328 | Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. |
| Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q38369233 | Deep sequencing reveals the mitochondrial DNA variation landscapes of breast-to-brain metastasis blood samples |
| Q34495985 | Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity |
| Q57110841 | Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations |
| Q37821014 | Development of genetic testing for breast, ovarian and colorectal cancer predisposition: a step closer to targeted cancer prevention. |
| Q24650735 | Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification |
| Q55110745 | E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. |
| Q33732330 | Economic and Practical Factors in Diagnosing HNPCC Using Clinical Criteria, Immunohistochemistry and Microsatellite Instability Analysis |
| Q52838313 | Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. |
| Q34901055 | Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome |
| Q36245609 | Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers |
| Q38720533 | Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci |
| Q24633316 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer |
| Q36487146 | Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk |
| Q57742231 | Establishing pathogenicity of germline mismatch repair gene mutations: A Bayesian model |
| Q33792801 | Ethical, social and economic issues in familial breast cancer: a compilation of views from the E.C. Biomed II Demonstration Project |
| Q37459580 | Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study |
| Q36966218 | Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study |
| Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
| Q33894527 | Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium |
| Q34806825 | Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. |
| Q57266727 | Evaluation ofRAD50 in familial breast cancer predisposition |
| Q34613604 | Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers |
| Q47958061 | Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. |
| Q73883821 | Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome |
| Q34023407 | Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids |
| Q57266826 | Familial breast cancer: an investigation into the outcome of treatment for early stage disease |
| Q36243757 | Familial non-BRCA1/BRCA2-associated breast cancer |
| Q40531279 | Fibroadenoma with atypical giant cells occurring in Li Fraumeni Syndrome. |
| Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q114182808 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element |
| Q34535544 | Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. |
| Q36956156 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer |
| Q34017597 | Gene-gene interactions in breast cancer susceptibility |
| Q33589487 | Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes |
| Q62583319 | Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk |
| Q54099249 | Genetic testing for BRCA1 mutation in the UK. |
| Q37365746 | Genetic testing for breast cancer predisposition in 1999: which molecular strategy and which family criteria? |
| Q64004365 | Genetic testing for young women with breast cancer – Authors' reply |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q36218993 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q34514955 | Genome-wide association of breast cancer: composite likelihood with imputed genotypes |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q29417100 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q34114293 | Genome-wide association study identifies five new breast cancer susceptibility loci |
| Q24645441 | Genome-wide association study identifies novel breast cancer susceptibility loci |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q24628710 | Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q33778612 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. |
| Q47552886 | Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study |
| Q27852185 | Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer |
| Q57266552 | Germline RAD51C mutations confer susceptibility to ovarian cancer |
| Q28245028 | Germline mutations in RAD51D confer susceptibility to ovarian cancer |
| Q45733546 | Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women |
| Q33792814 | Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer |
| Q64004362 | Hereditary Breast and Ovarian Cancer Testing in the Genomic Era |
| Q35914662 | Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. |
| Q46935200 | High-grade ER-negative tumour breast cancers are characteristic of both very young onset cases and patients with hereditary breast cancer. |
| Q37121271 | High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium |
| Q57387443 | IPOS 9th World Congress Abstracts |
| Q37006170 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. |
| Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
| Q57053903 | Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q28943279 | Identification of inherited genetic variations influencing prognosis in early-onset breast cancer |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q37039765 | Identification of personal risk of breast cancer: genetics |
| Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q41684510 | Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen |
| Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
| Q52642370 | Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study. |
| Q45681672 | Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. |
| Q33237559 | Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers |
| Q64004366 | Information required for surgical decision making in young women with breast cancer |
| Q38708423 | Information requirements of young women with breast cancer treated with mastectomy or breast conserving surgery: A systematic review |
| Q34996647 | Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer |
| Q46565114 | Inherited predisposition to colorectal adenomas caused by multiple rare alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3. |
| Q37684424 | Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration |
| Q37364207 | Insurance implications for individuals with a high risk of breast and ovarian cancer in Europe |
| Q34081324 | Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer |
| Q92313654 | Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification |
| Q37725393 | Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome |
| Q53509871 | Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. |
| Q43076324 | Linkage analysis of 56 multiplex families excludes the Cowden disease gene PTEN as a major contributor to familial breast cancer. |
| Q39562817 | Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study |
| Q56435837 | Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial |
| Q42314706 | Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas |
| Q45167839 | Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas |
| Q28215462 | Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations |
| Q34700093 | Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status |
| Q57742261 | MYH polyposis: A new autosomal recessive form of familial adenomatous polyposis due to defective base excision repair-reappraisal of genetic risk and family management |
| Q27016591 | Machine learning approaches for the discovery of gene-gene interactions in disease data |
| Q51820769 | Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. |
| Q40115245 | Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02). |
| Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
| Q49252742 | Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer. |
| Q24799978 | Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer |
| Q28388006 | Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q36785681 | Mutation and association analysis of GEN1 in breast cancer susceptibility |
| Q33891865 | Mutation scanning by meltMADGE: validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general population |
| Q52182349 | Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases. |
| Q26799669 | Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q30275832 | No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q37308596 | No evidence that GATA3 rs570613 SNP modifies breast cancer risk |
| Q57266769 | Non-Uptake of Predictive Genetic Testing for BRCA1/2 among Relatives of Known Carriers: Attributes, Cancer Worry, and Barriers to Testing in a Multicenter Clinical Cohort |
| Q46538007 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study |
| Q37996988 | Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study |
| Q57266724 | Optimal Selection of Individuals for BRCA Mutation Testing |
| Q57759858 | Oral Presentations |
| Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q24615080 | PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene |
| Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q58455760 | Paucimorphic Alleles versus Polymorphic Alleles and Rare Mutations in Disease Causation: Theory, Observation and Detection |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q36071595 | Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy |
| Q33921008 | Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium |
| Q31152672 | Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics |
| Q92055460 | Prediction and clinical utility of a contralateral breast cancer risk model |
| Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q53080407 | Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6. |
| Q36610024 | Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up |
| Q36644314 | Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort |
| Q36168475 | Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS) |
| Q57266592 | Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer |
| Q37103047 | Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. |
| Q47232801 | Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment |
| Q37350137 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups |
| Q46943414 | Prospective Study of Outcome in Sporadic versus Hereditary Breast Cancer: pros and cons of running a cohort study. |
| Q44358008 | Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study |
| Q33294128 | Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol |
| Q49340500 | Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. |
| Q54944326 | Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. |
| Q91259221 | Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY) |
| Q36696244 | Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort |
| Q64004364 | Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations |
| Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
| Q35648055 | Quantifying the cumulative effect of low-penetrance genetic variants on breast cancer risk |
| Q47666000 | RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer |
| Q54501613 | RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1. |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q63457810 | Renewed: Protocol for a randomised controlled trial of a digital intervention to support quality of life in cancer survivors |
| Q57269829 | Response: Table 1 |
| Q36490048 | Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule |
| Q37363639 | Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer |
| Q36897112 | Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study |
| Q37624504 | Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10 |
| Q48833793 | Risk reducing mastectomy: outcomes in 10 European centres. |
| Q52724999 | Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. |
| Q43052119 | Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. |
| Q41983219 | Screening SMAD1, SMAD2, SMAD3, and SMAD5 for germline mutations in juvenile polyposis syndrome |
| Q50767903 | Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. |
| Q34788325 | Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results |
| Q36089391 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer |
| Q61118451 | Shared heritability and functional enrichment across six solid cancers |
| Q64004349 | Shared heritability and functional enrichment across six solid cancers |
| Q64004372 | Skin spots and heart tumors |
| Q38077865 | Stratified cancer screening: the practicalities of implementation |
| Q34872901 | Support Vector Machine classifier for estrogen receptor positive and negative early-onset breast cancer. |
| Q51624037 | Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. |
| Q49964503 | Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer. |
| Q35020403 | Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer |
| Q33927384 | Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study |
| Q46935108 | Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study |
| Q35000282 | The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services |
| Q36615665 | The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions |
| Q45973022 | The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. |
| Q38793676 | The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium |
| Q24806265 | The DNMT3B C-->T promoter polymorphism and risk of breast cancer in a British population: a case-control study |
| Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
| Q64116004 | The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations |
| Q52673733 | The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. |
| Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
| Q37762190 | The influence of common polymorphisms on breast cancer |
| Q37131378 | The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer |
| Q57074665 | The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review |
| Q35024008 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
| Q34120685 | Therapeutic targeting of integrin αvβ6 in breast cancer |
| Q92952990 | Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q58797082 | Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing |
| Q56625730 | Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles |
| Q34252077 | Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. |
| Q33899892 | Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression |
| Q92994868 | Two truncating variants in FANCC and breast cancer risk |
| Q37365192 | Utilisation of prophylactic mastectomy in 10 European centres |
| Q64004368 | Validating “Image box”-a new approach to multicentre radiology reviews using a web-based image review system: study protocol |
| Q33904964 | Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility |
| Q56342454 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility |
| Q90169993 | Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation |
| Q33847791 | Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer |
| Q56334023 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology |
Search more.